Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 2, 2004, Pages 219-231

  Treiber, G ^a   Schwabe, M ^b   Ammon, S ^c   Walker, S ^d   Klotz, U ^c   Malfertheiner, P ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b BAG Company   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d Hospital of Bietigheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; RANITIDINE;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST RANGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SMOKING; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; ALCOHOL DRINKING; ASPIRIN; COHORT STUDIES; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 0842330079     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01751.x     Document Type: Article

References (60)

1. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. II): 1137-42.
2. Nyren O, Lindberg G, Lindstrom E, et al. Economic costs of functional dyspepsia. Pharmacoeconomics 1992; 1: 312-24.
3. Treiber G, Malfertheiner P. Economic aspects of Helicobacter pylori eradication therapy - where are we now? Gesundh ökon Qual Manag 2001; 6: 145-51.
4. Briggs AH, Sculpher MJ, Logan RPH, et al. Cost-effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996; 312: 1321-5.
5. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996; 91: 1773-7.
6. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population based study. Gastroenterology 1992; 102: 1259-68.
7. Veldhuyzen van Zanten SJ, Tytgat KM, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993; 46: 273-9.
8. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-86.
9. Mansi C, Savarino V, Mela GS, et al. Are clinical patterns of dyspepsia a valid guideline for appropriate use of endoscopy? A report on 2253 dyspeptic patients. Am J Gastroenterol 1993; 88: 1011-5.
10. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994; 106: 1174-83.
11. Nyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986; 314: 339-43.
12. Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of anti-secretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 312-20.
13. Talley N, Meineche-Schmidt V, Pare P, et al. Effect of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
14. Kuo B, Camilleri M, Burton D, et al. 5-HT3 antagonism of upper gastrointestinal symptoms after a dyspepsia inducing meal. Gastroenterology 2001; 120(Suppl.): A133(Abstract).
15. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660-73.
16. Bernersen B, Johnson R, Bostad L, et al. Is Helicobacter pylori the cause of dyspepsia? Br Med J 1992; 304: 1276-9.
17. Strauss RM, Wang TC, Kelsey PB, et al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients under-going gastroduodenoscopy. Am J Med 1990; 89: 464-9.
18. Schubert TT, Schubert AB, Ma CK. Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy. Gastrointest Endosc 1992; 38: 357-60.
19. Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and non-ulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113: S67-77.
20. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol 1996; 215: 38-47.
21. Jakkimainen RL, Boyle E, Tudiver F, et al. Is Helicobacter associated with non ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. Br Med J 1999; 319: 1040-4.
22. McColl K, Malfertheiner P. Helicobacter pylori and functional dyspepsia. Curr Opin Gastroenterol 2000; 16(Suppl.): S29-32.
23. Laheij RJ, Jansen JB, Vandelisdonk EH, et al. Symptom improvement through eradication of Helicobacter pylori with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10: 843-50.
24. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321: 659-64.
25. Laine L, Schoenfeld P, Fennerty MB. H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: meta-analysis of randomised controlled trials. Ann Intern Med 2001; 134: 361-9.
26. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 1869-74.
27. Talley NJ, Vakil N, Ballard D, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106-11.
28. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double-blind placebo controlled trial with 12 months follow up. Br Med J 1999; 318: 833-7.
29. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1875-81.
30. Malfertheiner P, Fischbach W, Layer P, et al. ELAN study proves symptomatic benefit of Helicobacter pylori eradication in functional dyspepsia. Gastroenterology 2000; 118(Suppl.): A440(Abstract).
31. Loffeld RJ, Werdmuller BF, Kusters JG, et al. Functional dyspepsia is associated with cagA-positive Helicobacter pylori strains. Scand J Gastroenterol 2001; 36: 351-5.
32. Heikkinen M, Mayo K, Megraud F, et al. Association of CagA-positive and CagA-negative Helicobacter pylori strains in patients' symptoms and gastritis in primary care patients with functional upper abdominal complaints. Scand J Gastroenterol 1998; 33: 31-8.
33. Parente F, Imbesi V, Maconi G, et al. Influence of bacterial CagA status on gastritis, gastric function indices and pattern of symptoms in H. pylori positive dyspeptic patients. Am J Gastroenterol 1998; 93: 1073-9.
34. Holtmann G, Talley NJ, Mitchell H, et al. Antibody response to specific H. pylori antigens in functional dyspepsia, duodenal ulcer disease, and health. Am J Gastroenterol 1998; 93: 1222-7.
35. Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication - a randomized controlled trial (MACLOR STUDY). Arch Intern Med 2002; 162: 153-60.
36. Ammon S, Treiber G, Kees F, et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 759-66.
37. Yamaoka Y, Kikuchi S, El-Zimaity H, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123: 414-24.
38. Yamaoka Y, Kodama T, Graham DY, et al. Search for putative virulence factors of Helicobacter pylori: the low-molecular-weight (33-35 K) antigen. Dig Dis Sci 1998; 43: 1482-7.
39. Aucher P, Petit M, Mannant P, et al. Use of immunoblot assay to define serum antibody patterns associated with Helicobacter pylori infection and with Helicobacter pylori-related ulcers. J Clin Microbiol 1998; 36: 931-6.
40. Chua TS, Fock KM, Chan YH, et al. Seroreactivity to 19.5-kD antigen in combination with absence of seroreactivity to 35-kD antigen is associated with an increased risk of adenocarcinoma. Helicobacter 2002; 7: 257-64.
41. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000; 355: 1665-9.
42. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia. Arch Intern Med 1999; 159: 2283-8.
43. Veldhuyzen van Zanten SJ. A systematic overview of outcome measures in Helicobacter pylori gastritis trials and functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl. 199): 40-3.
44. Svedlund J, Sjodin I, Doterval G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
45. El-Omar EM, Banerjee S, Wirz A, et al. The Glasgow Dyspepsia Severity Score - a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol 1996; 8: 967-71.
46. Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia; responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther 2001; 15: 207-16.
47. McColl KE, el-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998; 42: 618-22.
48. Fendrick AM, Chey WD, Margaret N, et al. Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Am J Med 1999; 107: 133-6.
49. Nandurkar S, Talley NJ, Xia H, et al. Dyspepsia in the community is linked to smoking and aspirin but not to Helicobacter pylori infection. Arch Intern Med 1998; 158: 1427-33.
50. Sung J, Leung W, Go M, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 729-35.
51. McKendrick MW, Read NW. Irritable bowel syndrome - post salmonella infection. J Infect 1994; 29: 1-3.
52. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996; 347: 150-3.
53. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997; 314: 779-82.
54. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49: 743-5.
55. Bielefeldt K, Ozaki N, Gebhart G. Mild gastritis alters voltage-sensitive sodium currents in gastric sensory neurons in rats. Gastroenterology 2002; 122: 752-61.
56. Wildner-Christensen M, Moeller Hansen J, Schaffalitzky de Muckadell O. Effect of Helicobacter pylori screening and treatment in 20,000 inhabitants in the County of Funen, Denmark - one year follow-up. Gastroenterology 2002; 122(Suppl. 1): A1531(Abstract).
57. Lane JA, Harvey RF, Murray LJ, et al. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population: Study design and response rates of the British Helicobacter Project. Control Clin Trials 2002; 23: 321-32.
58. Spiegel B, Vakil N, Ofman J. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85.
59. Chiba N, Van Zanten S, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. Br Med J 2002; 324: 1012-6.
60. Treiber G, vanDoorn LJ, Rudi J, et al. The importance of the pretherapeutic cag-A status for the success of Helicobacter pylori eradication therapy. Gastroenterology 2001; 120(Suppl. 1): A582(Abstract).